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Abstract
Background: Osteosarcoma (OS) is the most common primary bone tumor in both humans and dogs and is the
second leading cause of cancer related deaths in children and young adults. Limb sparing surgery along with
chemotherapy has been the mainstay of treatment for OS. Many patients are not cured with current therapies,
presenting a real need for developing new treatments. Histone deacetylase (HDAC) inhibitors are a promising new
class of anticancer agents. In this study, we investigated the activity of the novel HDAC inhibitor AR-42 in a panel of
human and canine OS cell lines.
Methods: The effect of AR-42 and suberoylanilide hydroxamic acid (SAHA) alone or in combination with doxorubicin
on OS cell viability was assessed. Induction of histone acetylation after HDAC inhibitor treatment was confirmed by
Western blotting. Drug-induced apoptosis was analyzed by FACS. Apoptosis was assessed further by measuring
caspase 3/7 enzymatic activity, nucleosome fragmentation, and caspase cleavage. Effects on Akt signaling were
demonstrated by assessing phosphorylation of Akt and downstream signaling molecules.
Results: AR-42 was a potent inhibitor of cell viability and induced a greater apoptotic response compared to
SAHA when used at the same concentrations. Normal osteoblasts were much less sensitive. The combination of
AR-42 with doxorubicin resulted in a potent inhibition of cell viability and apparent synergistic effect. Furthermore, we
showed that AR-42 and SAHA induced cell death via the activation of the intrinsic mitochondrial pathway
through activation of caspase 3/7. This potent apoptotic activity was associated with the greater ability of AR-42
to downregulate survival signaling through Akt.
Conclusions: These results confirm that AR-42 is a potent inhibitor of HDAC activity and demonstrates its ability
to significantly inhibit cell survival through its pleiotropic effects in both canine and human OS cells and suggests
that spontaneous OS in pet dogs may be a useful large animal model for preclinical evaluation of HDAC inhibitors.
HDAC inhibition in combination with standard doxorubicin treatment offers promising potential for chemotherapeutic
intervention in both canine and human OS.
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Background
Osteosarcoma (OS) is the most common primary malig-
nant bone tumor in humans, affecting primarily adoles-
cents. Metastasis occurs frequently, with the lungs being
the most common metastatic site. Metastases occur in
greater than 80% of affected individuals treated with sur-
gery alone. Despite aggressive treatment, about a third
of affected patients die of their disease. Current treat-
ment with neoadjuvant chemotherapy followed by surgi-
cal resection and additional adjuvant chemotherapy
results in a 5-year-survival rate of 60–70% for people
with non-metastatic osteosarcoma treated with combina-
tions of methotrexate, cisplatin, doxorubicin and ifosfa-
mide [1]. Survival rates have improved little over the past
30 years, necessitating the development of new thera-
peutic approaches.
Spontaneous OS in the dog is an excellent large animal
model for the human disease. Interestingly, OS is also the
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most common primary bone tumor in dogs, occurring in
the canine population with an estimated incidence of at
least 13.9/100,000 [2] compared to the human incidence
of 1.02/100,000 [3]. The pathobiological, clinical, and mo-
lecular characteristics of the disease in humans and dogs
are quite similar. Dysregulated expression of ezrin, Met,
STAT3, Her2/Neu, overlapping transcriptional profiles,
and extreme genomic instability are among the shared
molecular characteristics in OS in the two species. As in
people, OS in dogs is an invasive rapidly growing cancer
with a high metastatic potential, primarily to lung and
bone. The median survival time for affected dogs treated
with amputation or limb sparing surgery and chemo-
therapy with a platinum drug or doxorubicin is 9–12
months, with most dogs eventually dying from metastatic
disease. As with people, survival times have not improved
appreciably since incorporation of the adjuvant chemo-
therapy [4]. Clearly, new treatment approaches are needed
to improve outcomes for OS in both humans and dogs.
Histone acetylation plays a significant role in tran-
scriptional regulation by altering the structure of chro-
matin. Acetylation of core histones is regulated by the
opposing activities of histone acetyl transferases (HATs)
and histone deacetylases (HDACs) that alter the tran-
scriptional status of the chromatin [5, 6]. HATs catalyze
transfer of acetyl groups to NH2-terminal lysine resi-
dues in histones that results in an open chromatin con-
formation and transcriptional activation by increasing
the accessibility of transcriptional machinery. In contrast,
recruitment of the HDAC complex results in chromatin
condensation and transcriptional repression [6]. Thus,
aberrant recruitment of the HDAC complex represses the
transcription of specific tumor suppressor genes resulting
in aberrant regulation of gene expression [7]. Several lines
of evidence indicate that altered HATand HDAC activities
are mechanistically linked to pathogenesis of a variety of
cancers as well as other diseases [7]. Therefore, HATs and
HDACs are promising targets for therapeutic interven-
tions as they are directed to reversing the aberrant epi-
genetic modifications in neoplastic cells in contrast to
genetic mutations that are irreversible [8]
HDAC inhibitors represent a class of anticancer agents
that modulate the transcription of target genes by regu-
lating the access of transcription factors and RNA poly-
merases to the promoter regions. In this context, many
HDAC inhibitors have been developed and extensively
investigated for their potential for anticancer treatment,
resulting in the FDA approval of Zolinza (vorinostat),
Istodax (romidepsin) and Beleodaq (belinostat) for the
treatment of cutaneous and peripheral T cell lymphoma
and Farydak (panobinostat) for multiple myeloma. Other
HDAC inhibitors continue to be evaluated in preclinical
studies and clinical trials [9]. HDAC inhibitors have
been shown to induce tumor cell death, promote
differentiation, suppress cell proliferation and cell cycle
progression in vitro and inhibit angiogenesis, reduce
tumor growth, and enhance immune responses of the
host in vivo [8].
AR-42 (formerly known as OSU-HDAC42; Arno Thera-
peutics, Inc., Flemington, NJ) is a novel phenylbutyrate-
based class I/IIB HDAC inhibitor originally [10] developed
by our group and currently in clinical trials for
hematologic malignancies. In preclinical studies, AR-42
was evaluated in vitro and in vivo in models of human
prostate cancer [11], ovarian [12] and hepatocellular
carcinoma [13], myeloma [14] and other B-cell malig-
nancies [15], and a variety of canine cancers [16, 17].
For the most part, these studies have focused on antitumor
activity in carcinomas and hematopoietic cancers. In this
study, we investigate the antitumor effects of AR-42 in OS,
an aggressive, highly malignant bone tumor of mesen-
chymal origin and the most common primary bone
tumor of children and dogs. These data show that AR-42
is a potent inhibitor of OS cell viability and induces apop-
tosis. Furthermore, we show that AR-42 induces cell death
via the activation of the intrinsic mitochondrial pathway
through activation of caspase 3/7. This potent apoptotic
activity is associated with the down regulation of survival
pathways including Akt signaling and expression of survi-
vin and Bcl-xl. In general, these effects of AR-42 were
achieved with greater potency compared to suberoyla-
nilide hydroxamic acid (SAHA; aka vorinostat), another
pan-HDAC inhibitor. These results indicate that HDAC
inhibitors may have therapeutic potential against both
human and canine OS.
Methods
Reagents
The HDAC inhibitors AR-42 and SAHA were synthesized
as described [10]. Stock solutions AR-42 and SAHA were
prepared in DMSO and diluted in the indicated culture
medium for treatment of cells in vitro. Antibodies
against Akt, pAkt-Ser473, phosphor-glycogen synthase
kinase-3 (GSK3)β, caspase-3, Bcl-xl, α-tubulin, cyclin
D1, phosphor-p70 ribosomal protein S6 kinase (p70S6K),
p-mTOR and PTEN were purchased from Cell Signaling
Technologies (Beverly, MA). Additional polyclonal rabbit
antibodies used were acetylated histones H3 (N-terminus)
and H4 (Lys5/8/12/16) (Upstate Biotechnology, Inc.,
Lake Placid, NY), β-actin (Sigma, St. Louis, MO), and
survivin (Novus Biologicals, Littleton, CO).
Cell lines and cell culture
Canine OS cell lines, OSCA-2, −7.2, −16, −36, −39.1,
−40, −50, were previously established in the laboratory
of one of the authors (JFM). Normal canine osteoblasts
were obtained from Cell Applications, Inc. (San Diego,
CA). The canine OS cell line D17 and human OS cell
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lines SAOS-2, SJSA and U2OS were obtained from
American Type Culture Collection (Manassas, VA). Cells
were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) (OSCA-2, −16, −36, −39.1, −40, −50), RPMI-
1640 (D17, OSCA-7.2), or McCoy’s medium (Gibco,
Invitrogen, Carlsbad, CA) (SJSA, SAOS-2 and U2OS)
supplemented with 10% fetal bovine serum (FBS,
HyClone, Gemini, West Sacramento, CA) and antibiotics
(100 U/ml penicillin, 0.1 mg/ml streptomycin) (Gibco)
in a humidified incubator containing 5% CO2 at 37 °C.
Cell viability assays
The effect of AR-42 and SAHA on the viability of
canine and human tumor cells was assessed by the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay (Sigma) as described previously [18]. Briefly,
cells were seeded in 96-well plates at ~2500 cells per
well in medium supplemented with 10% FBS. After
24 h, the cells were treated with varying concentrations
(1–10 μM) of AR-42 and SAHA, dissolved in DMSO
(final DMSO concentration ≤ 0.1%) for 24, 48 and 72 h.
Controls were treated with DMSO vehicle alone at a
concentration equal to that of drug-treated cells. After
drug treatment, 22 μl of MTT reagent (5 mg/ml) was
added to each well and the cells were incubated for up
to 2 to 4 h at 37 °C. The absorbance was read on a plate
reader (UV Spectromax M2 plate reader, Molecular
Devices, Sunnyvale, CA) at 570 nm. The concentration
of AR-42 and SAHA that inhibited cell viability by 50%
(IC50) was determined using CompuSyn software (v. 3.0.1,
ComboSyn, Inc., Paramus, NJ) and the values expressed
as mean ± SD. All treatments were evaluated in triplicate
in at least three independent experiments.
Cell cycle analysis
Cells were exposed to AR-42 or SAHA at 1 and 10 μM
concentrations for 48 h, washed with phosphate-
buffered saline (PBS), resuspended in 500 μl of cold PBS,
and then added drop wise to 70% ethanol and stored at
4 °C overnight. Cells were then washed twice in PBS and
suspended in 500 μl of PBS containing 10 ug/ml of
RNase A (LC, Laboratories, Woburn, CA) and 50 ug/ml
of propidium iodide (Sigma) and assessed by BD FACS
Calibur (Becton-Dickinson, San Jose, CA). Data were
analyzed by Cell Quest flow software (Becton-Dickinson).
A maximum of 10,000 cells within the gated region were
analyzed for each treated and untreated sample. Experi-
ments were replicated three times.
Cell death detection ELISA
Drug-induced apoptotic cell death was determined by
detection of DNA fragmentation using the Cell Death
Detection ELISA kit (Roche, Indianapolis, IN). The
ELISA was performed according to the manufacturer’s
protocol and is based on the quantitative determination
of cytoplasmic histone-associated DNA fragments in the
form of mononucleosomes or oligonucleosomes generated
after induced apoptotic death. Briefly, 3 × 105 cells were
cultured in RPMI/McCoy’s medium supplemented with
10% FBS in 100 mm tissue culture dishes for 24 h before
treatment. Cells were treated with varying concentrations
of AR-42 and SAHA (1–10 μM) and DMSO vehicle as
control for 48 h. Approximately 100,000 cells were used
per assay. The absorbance was read on a plate reader (UV
Spectromax M2 plate reader, Molecular Devices) at a
wavelength of 405–490 nm.
Measurement of caspase 3/7 activity
Activation of the caspase 3/7 pathway following the drug
treatment was measured by Sensolyte™ Homogeneous
AMC Caspase-3/7 Assay kit (AnaSpec, San Jose, CA)
following the manufacturer’s protocol. Briefly, 1x105
cells per well were seeded in six-well plates and treated
for 48 h at concentrations of 1 and 10 μM AR-42 or
SAHA. Each treatment was performed in triplicate. After
treatment for the indicated time, cells were lysed with
lysis buffer to a final volume of 150 μl/well and 50 μl of
caspase 3/7 substrate reagent was then added to the
wells and incubated on a plate shaker for 30–60 s at
100–200 rpm. Fluorescence were read on a plate reader
(UV Spectromax M2 plate reader, Molecular Devices) at
an Ex/Em = 354 nm/442 nm and recorded after 1 h.
Immunoblotting
For immunoblotting analysis, drug-treated (AR-42 and
SAHA at 1 and 10 μM) and vehicle (DMSO)-treated
cells were collected 48 h after treatment, washed in PBS,
and lysed in M-PER protein extraction reagent (Pierce
Biotechnology, Rockford, IL) unless otherwise stated.
After centrifugation at 14,000 rpm for 15 min equal
amounts of total protein from the cell lysates were
resolved on 4–20% denaturing polyacrylamide gels (Invi-
trogen) and transferred to nitrocellulose membranes
(PALL-Germany). After blocking with TBST containing
5% non-fat dry milk (Blotto, BioRad Laboratories,
Hercules, CA) for 1 h, the membranes were incubated
with indicated primary antibodies at 4 °C overnight and
then washed three times with TBST. The membranes
were probed with horseradish peroxidase conjugated
secondary antibodies (Jackson Immune Research Labora-
tories, West Grove, PA) for 1 h at room temperature and
washed three times with TBST. The blots were then
developed with Western Lightning reagents (Perkin-
Elmer, Waltham, MA).
Drug combination studies
The effect of combining AR-42 with doxorubicin on
cancer cell viability was evaluated in U2OS and D17 cells
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using the fixed-ratio method. Cells were treated with AR-
42 and doxorubicin individually and in combination. For
combination treatment of U2OS cells, drugs were com-
bined at a concentration ratio of 3.3:1 (AR42:doxorubicin)
and 2-fold serial dilutions were performed to generate a
series of solutions containing AR-42 and doxorubicin at
concentrations ranging from 0.125 to 8 μM and 0.0375
to 2.4 μM, respectively. For treatment of D17 cells, the
concentrations of AR-42 in the combination ranged
from 0.625 to 40 μM, and that of doxorubicin ranged
from 0.04125 to 2.64 μM to yield a fixed concentration
ratio of 15.2:1 (AR-42:doxorubicin). After treatments,
cell viability was determined by MTT assays as described
above. Dose-effect data for individual drugs and their
combinations were analyzed for synergistic effects using
the median-effect method of Chou and Talalay [19] using
CompuSyn software (v. 3.0.1, ComboSyn, Inc.). Com-
bination index (CI) values were calculated to characterize
the nature of the drug interaction as defined by Chou
and Talalay: CI = 1, additivity; CI < 1, synergism; CI > 1,
antagonism. The dose reduction index (DRI) is a measure
of the extent to which the dose of a drug in a synergistic
combination is reduced, compared with the dose of the
same drug alone, to achieve a given effect level. The DRI
value for each drug was also calculated.
Statistical analysis
Cell viability was measured in triplicate and averaged to
achieve a single value for each combination of drug
treatment, concentration, and cell line. The results were
plotted over the three measurement periods and visually
inspected (Fig. 1c). The cell viability at 72 h was com-
pared by drug treatment assignment, AR-42 (n = 24) ver-
sus SAHA (n = 24). Samples were tested for normality
(D ’Agostino-Pearson test) and equality of variance
(Levene’s test). Inasmuch as samples were not normally
distributed, a Mann-Whitney test for independent sam-
ples was performed to compare cell viability by drug
treatment group. Analyses were performed using com-
mercial software (MedCalc Statistical Software version
16.8, MedCalc Software bvba, Ostend, Belgium). Statistical
significance was set at P < 0.05.
Results
HDAC inhibitors AR-42 and SAHA reduce viability of
canine and human OS cells in a dose-dependent manner
The antiproliferative effects of AR-42 and SAHA were
assessed in three human (SAOS-2, SJSA and U2OS) and
eight canine (D17, OSCA-2, −7.2, −16, −36, −39.1, −40
and −50) OS cell lines. OS cells were treated with each
drug over a concentration range of 0.1 to 10 μM and cell
viability was measured by MTT assay at 24, 48 and 72 h
of treatment. AR-42 caused dose-dependent reductions
in cell viability in all of the human cell lines starting at
48 h of treatment, except in SJSA cells for which a
decrease in viability was not seen until 72 h (Fig. 1a; 24
and 48 h data for SJSA are not shown). Similarly, AR-42
reduced cell viability in most of the canine cell lines,
which, however, exhibited differential sensitivities ranging
from near complete resistance (OSCA-39.1) to IC50
values of <1 μM at 72 h of treatment (D17, OSCA-2 and
OSCA-50) (Fig. 1b). OSCA-16, −7.2 and −36 cell lines
were relatively resistant. The IC50 values for sensitive
human and canine OS cells ranged from 0.25 to 2.2 μM
after 72 h of treatment. Comparison of the antiprolifer-
ative activities of AR-42 and SAHA was performed in
sensitive human (U2OS, SAOS-2) and canine (D17,
OSCA-2) OS cell lines which showed that both inhibi-
tors induced time- and dose-dependent decreases in
cell viability and that, in all the cell lines tested, AR-42
was more potent than SAHA (Fig. 1c). Finally, the sen-
sitivity of non-malignant canine osteoblasts to AR-42
relative to human (SAOS-2, U2OS) and canine (OSCA-2,
D17) OS cells was determined. As shown in Fig. 1d, the
median percent cell viability at 72 h was significantly
greater for SAHA-treated cells (Z = 2.474, P = 0.0133).
This effect appeared to be present at all dilutions of the
drugs and in all cell-lines, although the magnitude of the
differences varied with combinations of drug concentra-
tion and cell lines.
Reduced cell viability correlates with increased apoptosis
The antitumor effects of HDAC inhibitors have been
linked to their ability to inhibit growth and induce apop-
tosis in cancer cells. To determine the ability of AR-42
to induce apoptosis in OS cells, we analyzed the effects
of AR-42 and SAHA treatment on OS cells by cell cycle
analysis, quantitation of nucleosome fragmentation, and
measurement of caspase activity. Both inhibitors induced
dose-dependent apoptosis as indicated by an increased
sub-G1 cell population after 48 h of drug treatment,
which inversely correlated with a reduced percentage of
cycling cells, confirming decreased cell proliferation
(Fig. 2a). Relative to SAHA, AR-42-treated cells exhibited
a significantly greater increase in apoptosis at the 1 μM
concentration in all cell lines tested (Fig. 2a). Increases
in nucleosome fragmentation paralleled those in the
subG1 cell population (Fig. 2b). Furthermore, both
HDAC inhibitors increased caspase 3/7 enzymatic
activity in all cell lines, consistent with activation of the
intrinsic apoptotic pathway (Fig. 2c). Lastly, Western
blotting demonstrated a dose-dependent increase in
caspase 3 cleavage and a decrease in Bcl-xl expression
following HDAC inhibition (Fig. 2d). These results
demonstrate that AR-42 induces apoptosis in both canine
and human OS cell lines at low micromolar drug
concentrations.
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HDAC inhibitors increased acetylation of histone H3 and
H4 in OS cells
The antitumor effects of HDAC inhibitors are often the
consequence of altered gene transcription resulting from
increased histone acetylation. To examine the relation-
ship between HDAC inhibition and histone acetylation
in OS cells we assessed the levels of acetylated histones
in OS cells following treatment with AR-42 or SAHA.
Western blot analysis after 48 h of treatment revealed a
dose-dependent induction of acetylated histones H3
and H4 in both human and canine OS cell lines (Fig. 3)
demonstrating that these drugs actively modulate chro-
matin by inhibiting HDAC activity in the tumor cell
lines. These effects on histone acetylation correlated
with the differential and dose-dependent effects of AR-42
and SAHA on cell viability and apoptosis.
Potent reduction in cell survival/viability is associated
with attenuation of AKT activation and downstream
signaling molecules
Both AR-42 and, to a lesser extent, SAHA have been
shown to decrease Akt phosphorylation in prostate cancer
cells [20] attributable to the disruption of HDAC-protein
phosphatase-1 (PP1) complexes leading to increased PP1-
Akt association [21]. Thus, we investigated the effects of
both drugs on Akt phosphorylation and downstream
markers of Akt signaling. Western blot analysis revealed
that, after 48 h of treatment with 10 μM of either AR-42
Fig. 1 Antiproliferative effect of HDAC inhibitors AR-42 and SAHA on human and canine osteosarcoma cells. a, b Dose-dependent effects of AR-42
on cell viability after 72 h of treatment in human (SJSA, SAOS-2, U2OS) and canine (D17, OSCA-2, OSCA-7.2, OSCA-16, OSCA-40, OSCA-36, OSCA-39.1,
OSCA-50,) OS cells. c Time- and dose-dependent effects of AR-42 and SAHA on cell viability in human (U2OS and SAOS-2) and canine (D17, OSCA-2)
OS cells. d Dose-dependent effects of AR-42 on cell viability after 72 h of treatment in human (SAOS-2, U2OS) and canine (D17, OSCA-2) OS cells and
normal canine osteoblasts. Cells were exposed to AR-42 or SAHA at the indicated concentrations for 24, 48 or 72 h and cell viability assessed by MTT
assay. Data presented are the average of triplicate determinations from three independent experiments
Murahari et al. BMC Cancer  (2017) 17:67 Page 5 of 11
or SAHA, pAkt-Ser473 was reduced in 2 of 3 human and 2
of 4 canine OS cell lines (data for D17 and SAOS-2
cells are shown, Fig. 4). Similarly, decreases in the
phosphorylation of GSK3β, a direct phosphorylation
target of Akt, were also observed in cells treated with
higher concentrations of drug, which confirmed the
functional suppression of Akt signaling in these HDAC
inhibitor-treated cells. HDAC inhibitor treatment also
caused reductions in the phosphorylation of mTOR
and its substrate, p70S6K, more prominently in D17
cells than in SAOS-2 cells, in which the effects were
small. The mTOR pathway is another downstream
effector of Akt signaling and its dysregulation has been
implicated in OS. At 1 μM AR-42 and SAHA, effects
on Akt signaling were inconsistent, ranging from minor
reductions to apparent lack of effect or even increases
in these signaling markers, which was unexpected in
light of clear effects of this concentration of drug on
cell viability, apoptosis, and/or histone acetylation.
Phosphatase and tensin homolog (PTEN) negatively
regulates Akt signaling by antagonizing the action of
phosphatidylinositol 3–kinase (PI3K) [22]. Thus, the
Fig. 2 HDAC inhibitors AR-42 and SAHA induce apoptosis of osteosarcoma cells. a Dose-dependent increase of apoptosis in OS cells treated with
AR-42 or SAHA as determined by analysis of cell cycle profiles by flow cytometry. Cells were exposed to DMSO, AR-42, or SAHA at the indicated
concentrations for 48 h. The percentage of propidium iodide stained sub G1 cells is shown. Representative data from three independent experiments
are presented. *p < 0.01, **p < 0.005, ***p < 0.0001. b Quantitation of caspase-3/7 enzymatic activity in OS cells treated with AR-42. OS cells
were exposed to DMSO, AR-42, or SAHA at the indicated concentrations for 48 h. Caspase-3/7 enzymatic activity was determined using the
SensoLyte® Homogeneous AMC Caspase-3 Assay Kit. *p < 0.01, **p < 0.005. c Dose-dependent effect of AR-42 on fragmented nucleosome
accumulation in treated OS cells. OS cells were exposed to DMSO, AR-42, or SAHA at the indicated concentrations for 48 h. Fragmented
cytoplasmic nucleosomal DNA was detected by Cell Death Detection ELISA Kit. *p < 0.001, **p < 0.0001. d Western blot analysis of apoptotic
markers. OS cells were exposed to AR-42 or SAHA at the indicated concentrations for 48 h. Protein lysates were generated and separated by
SDS-PAGE and Western blotting for caspase-3, Bcl-xL, and α-tubulin was performed
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effect of AR-42 on the expression of PTEN was also
assessed. Neither AR-42 nor SAHA altered the abun-
dance of PTEN protein in OS cell lines, suggesting that
PTEN was not involved in the HDAC inhibitor-
mediated suppression of pAkt-Ser473.
The up-regulation of survivin, an inhibitor of apoptosis
protein (IAP) family member, has been reported to be
associated with poor prognosis and increased risk of
metastasis in OS [23–25]. Previous studies have demon-
strated that HDAC inhibitors, including AR-42, can sup-
press survivin expression in cancer cells [13, 20, 26].
Moreover, survivin expression has been shown to be regu-
lated by the Akt/p70S6K1 pathway [27]. As shown in
Fig. 4, treatment with either HDAC inhibitor resulted in a
dose-dependent reduction of survivin in both human and
canine OS cells. These data suggest that AR-42 induces
apoptosis of OS tumor cell lines through modulation of
key cellular proteins.
AR-42 enhances the cytotoxic effects of doxorubicin
in OS cells
Several preclinical studies have described synergistic
effects of HDAC inhibitors in combination with a diverse
range of cytotoxic and targeted therapeutic agents [5].
AR-42 itself has been reported to sensitize prostate cancer
and hepatocellular carcinoma cells to DNA double-strand
break-inducing chemotherapeutic agents [28] and radio-
therapy [29], respectively. Consequently, we investigated
the potential synergistic activity of the combination of
AR-42 and doxorubicin in human and canine OS cells.
U2OS and D17 cells were treated with AR-42 and doxo-
rubicin over a range of doses both as single agents and in
Fig. 3 AR-42 and SAHA treatment enhanced histone acetylation in both human and canine osteosarcoma cells. OS cells were treated with DMSO
and the indicated concentrations of AR-42 or SAHA for 48 h. The acetylation status of histones H3 and H4 were determined by Western blotting.
β-actin was used as a loading control
Fig. 4 HDAC inhibition causes dose-dependent decreases in Akt phosphorylation and multiple downstream signaling molecules. D17 and SAOS-2 OS
cells were exposed to the indicated concentrations of AR-42, SAHA, and DMSO for 48 h. Protein lysates were generated and separated by SDS-PAGE
and Western blotting was performed with the indicated antibodies. Representative immunoblots showing dose-dependent effects of AR-42 and SAHA
on Akt and GSK3β phosphorylation and survivin. β-Actin was used as a loading control. Protein lysates of similarly treated cells were immunoblotted
with mTOR and p70S6K phospho-antibodies
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combinations containing the drugs at fixed concentration
ratios. The dose-effect data generated after single agent
and combination treatments of each cell line (Fig. 5) were
subjected to median-effects analysis from which CI (com-
bination index) values were derived to define the drug
interactions. As shown in Table 1, for both cell lines the
AR-42/doxorubicin combination was synergistic, as all CI
values were less than 1 at dose levels that reduced cell
viability by 50% (effective dose-50, ED50) or greater.
Calculation of the dose reduction index (DRI) values
revealed that, as a result of the synergism between AR-42
and doxorubicin, their IC50 values could be reduced
by 2.06-fold and 4.03-fold, respectively, in U2OS cells, and
1.40-fold and 4.57-fold, respectively, in D17 cells (Table 2).
Discussion
Although strategies for treating primary OS tumors are
generally effective, the development of metastasis, pri-
marily to lung, remains the most common cause of
mortality for patients. No significant improvements in out-
comes for patients have occurred since the incorporation
of neoadjuvant and adjuvant chemotherapy over 30 years
ago [1]. In a recent review of drug development strategies
for OS, it was emphasized that new therapeutic targets
are needed and that, where feasible, the inclusion of the
dog with naturally occurring OS is of great value for
defining the activity of new drugs [30]. In this study, we
used a comparative in vitro approach to investigate the
antitumor effects of a novel HDAC inhibitor, AR-42, in
human and canine OS cells.
DNA methylation and histone acetylation are important
epigenetic mechanisms that regulate gene transcription in
cells. HDAC inhibitors modulate chromatin structure
through hyperacetylation of histones that critically affect
transcription of various genes, including tumor sup-
pressors, and mediate their effects in a cell type
dependent manner [5, 7]. In cancer, HDAC inhibitors
mediate changes in expression of genes involved in
regulation of cell survival, growth, check point control,
apoptosis, differentiation, migration and angiogenesis.
In general, cancer cells appear to be more sensitive
than normal cells to the effects of HDAC inhibitors,
suggesting great potential for the development and
therapeutic use of these agents to treat cancer [5, 7].
AR-42 is a novel hydroxamate-tethered phenylbutyrate
derivative that inhibits both class-I and -II deacetylases;
i.e., it is a pan-HDAC inhibitor. Previously, we and
others reported that AR-42 significantly reduced cell
viability and proliferation and increased apoptosis in a
variety of human cancer cell lines, in vitro and in vivo;
primarily in carcinomas (e.g. prostate [11], hepatocel-
lular [13], ovarian [12] and hematopoietic cancers (e.g.
myeloma [14], chronic lymphocytic leukemia [15]). We
also have shown that AR-42 has antitumor effects in
canine cancer cells [16], including malignant mast
cells, where we showed that the antitumor effects of
AR-42 are mediated via down-regulation of constitutively
activated KIT [17]. In the former study, in addition to
demonstrating the antiproliferative effects of AR-42 in
canine carcinomas and malignant hematopoietic cells,
similar effects were observed in a single OS cell line. In
this study we further evaluated the effects of AR-42 in
both human and canine OS cell lines. Spontaneous OS
in people and dogs share common clinical, morphological,
genetic, and transcriptional profile characteristics, making
OS in the dog an excellent large animal preclinical model
for drug development [4].
The concentration range of AR-42 used for testing (up
to 10 μM) was selected based on previously published
data on AR-42’s activity in a variety of cancer cell types
and on the contention that relevant tissue concentra-
tions of >10 μM were unlikely to be achieved in vivo. In
support of this view, newly published pharmacokinetic
data on AR-42 showed good penetration in bone marrow
(6 μM) in leukemic mice following oral dosing of 40 mg/kg
thrice weekly for 2.5 weeks (Cheng et al., AAPS J,
18:737–45, 2016). In this study, both human and canine
OS cells showed greater sensitivity to treatment with
Fig. 5 The combination of AR-42 and doxorubicin have synergistic activity in osteosarcoma cells. Dose-response curves for D17 and U2OS cells
treated with AR-42 and doxorubicin alone and in combination. The concentrations plotted for the combination are those of doxorubicin. D17
and U2OS cells were treated for 72 h with various concentrations of either AR-42 or doxorubicin alone, or in combination, with a fixed ratio of
AR-42 to doxorubicin. Cell viability was assessed by MTT assay. Data presented is the average of triplicate determinations from two independent
experiments
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HDAC inhibitors compared to normal canine osteo-
blasts, suggesting tumor cell specific anti-apoptotic effects
of HDAC inhibition. The lower sensitivities of nonma-
lignant cells relative to the corresponding malignant
cell types to the effects of AR-42 have been reported
for various types of cells, including prostate epithelial
cells (20), oral keratinocytes (Bai et al., Oral Oncol,
47:1127, 2011), ovarian surface epithelial cells (12), and
hepatocytes (13). As anticipated, AR-42 increased histone
acetylation in all OS cell lines, although the extent to
which this occurred varied between cell lines. In all
sensitive cell lines, AR-42 significantly inhibited cell
viability and induced apoptosis at lower concentrations
than SAHA. Decreases in cell viability correlated with an
increase in apoptotic activity, as evidenced by an increase
in cleaved caspase 3 protein, increased caspase 3/7
enzymatic activity, cytoplasmic accumulation of frag-
mented nucleosomes, and an increase in the subG1 cell
population. Several other HDAC inhibitors, including tri-
chostatin A (TSA) [31], SAHA [31], FR901228 [32], and
MS-275 [33] have been shown to induce histone hyperace-
tylation and decrease cell viability in human OS cell lines.
Our results suggest that HDAC inhibitors have pleio-
tropic effects on OS cells in vitro, including increased
acetylation of histones, inhibition of Akt activity with
consequent effects on downstream effectors of Akt sig-
naling, including GSK3β, mTOR, and survivin, suppres-
sion of anti-apoptotic Bcl-xl expression, and activation
of intrinsic mechanisms of apoptosis in a dose-dependent
manner. These observations suggest that the potent anti-
tumor activity of HDAC inhibitors is due to the ability
to activate multiple antitumor mechanisms including
increased histone acetylation inducing increased gene
transcription, inhibition of cell survival and growth
through inhibition of Akt signaling, and increased
induction of apoptosis via the intrinsic pathway. Sur-
prisingly, the observed effects of the low dose (1 μM) of
AR-42 and SAHA on Akt signaling markers (Fig. 4)
were inconsistent with their effects on cell viability,
apoptosis and histone acetylation. Perhaps, these data
suggest that, under these conditions, Akt signaling is
not a major mediator of HDAC inhibitor-induced apop-
tosis in these cell types. Indeed, multiple pro-apoptotic
mechanisms in cancer cells have been implicated in the
anticancer effects of HDAC inhibition, including both
extrinsic and intrinsic apoptotic pathways, cell cycle
arrest, ROS production, and transcriptional induction
of pro-apoptotic BCL2 family genes [34, 35].
Recently, the aggressiveness of OS was linked to spe-
cific gene signatures that are due in part to modulation
of the epigenetic landscape by RB. These signatures
could be reversed to resemble less aggressive OS or nor-
mal bone by HDAC and DNA methyltransferase (DNMT)
inhibition with SAHA and Zebularine [36]. This may
explain why more aggressive tumors are more sensitive to
HDAC inhibition [37].
Importantly, the concentrations of AR-42 required to
induce histone acetylation, decrease cell proliferation,
and induce apoptosis occurred at low micromolar con-
centrations that are biologically relevant and correlated
with the inhibitory concentrations tested in other cancer
models. Furthermore, the combination of AR-42 and
doxorubicin resulted in a significant decrease in cell via-
bility compared to treatment with either agent alone,
suggesting synergistic effects of the drug combination
and a potential clinical use for OS therapy. Similarly,
although the weak HDAC inhibitor valproic acid did not
decrease OS cell viability at physiologically relevant con-
centrations, it did sensitize human and canine OS cells
to doxorubicin [38] and was well tolerated in combination
with doxorubicin in dogs with spontaneously occurring
solid tumors [39].
Conclusions
These data demonstrate that HDAC inhibitors induced
apoptosis and sensitized both human and canine OS
cells to cytotoxic chemotherapy. AR-42 was more potent
than SAHA as it reduced the viability of canine and
human OS cells at lower concentrations. Furthermore,
AR-42 enhanced the cytotoxic effects of doxorubicin, a
drug that is currently used for treatment of OS clinically.
These synergistic interactions can be further explored
for the treatment of OS in humans. These results further
validate the comparative oncology approach to drug
development for OS [40].
Table 2 Dose reduction index (DRI)a of AR-42 and doxorubicin
in osteosarcoma cell lines
U2OS AR-42 Doxorubicin
Single agent IC50 [μM] 2.55 1.45
Combination IC50 [μM] 1.24 0.36
DRI 2.06 4.03
D17 AR-42 Doxorubicin
Single agent IC50 [μM] 1.46 0.32
Combination IC50 [μM] 1.04 0.07
DRI 1.40 4.57
aDose reduction index (DRI) indicates the extent to which the concentration of
a drug can be reduced in the combination to achieve an effect level similar to
that achieved as a single agent
Table 1 Combination index (CI) values of AR-42 and doxorubicin
at the indicated effective dose (ED) in osteosarcoma cell lines
Cell Line ED50 ED75 ED90 ED95
D17 0.93 0.38 0.46 0.59
U2OS 0.74 0.23 0.07 0.03
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